Why This Overlooked Seattle Drugmaker Could be the Best Biotech Buy Right Now Post author:Sam Post published:November 28, 2017 Post category:BioPharma Omeros is getting a lot of love from investors and analysts these days. Source: BioSpace You Might Also Like Janssen R&D Release: Data At ASCO Show Consistent Progression-Free Survival Benefit In Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients Treated With Ibrutinib, Including Those With High-Risk Disease, With Up To Four Years Of Follow-Up June 4, 2017 <b>Elsevier</b> Launches Solution To Accelerate Drug Discovery Through Comprehensive Prediction And Assessment Of Drug-Drug Interactions June 18, 2017 KBP Biosciences Lands $76M, an Ex-GlaxoSmithKline Exec as Its New CEO and a HQ Move to Philly January 4, 2018
Janssen R&D Release: Data At ASCO Show Consistent Progression-Free Survival Benefit In Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients Treated With Ibrutinib, Including Those With High-Risk Disease, With Up To Four Years Of Follow-Up June 4, 2017
<b>Elsevier</b> Launches Solution To Accelerate Drug Discovery Through Comprehensive Prediction And Assessment Of Drug-Drug Interactions June 18, 2017
KBP Biosciences Lands $76M, an Ex-GlaxoSmithKline Exec as Its New CEO and a HQ Move to Philly January 4, 2018
